Agensys begins trial of novel antibody in prostate cancer
3rd Nov 2005, 02:36 GMT
Agensys has begun the first phase I clinical trial of its investigational antibody AGS-PSCA in patients with advanced prostate cancer.
Agensys begins trial of novel antibody in prostate cancer related news:
- Protein suppresses prostate cancer, enhances effects of vitamin E — KeralaNext: Science
- Benefit of combining radiation and hormone therapy in the treatment of prostate cancer — News-Medical News Feed
- Role of alpha tocopherol associated protein in prostate cancer — News-Medical News Feed
- Long-term hormone use helps prostate cancer patients live longer — KeralaNext: Science
- Testosterone replacement therapy for late onset hypogonadism: what is the risk of inducing prostate cancer? — Prostate Cancer and Prostatic Diseases
- Prostate cancer care needs improvement — OnMedica Latest News
- Concern over treatment of prostate cancer patients — Monsters and Critics News
- U-M scientists say fused genes trigger the development of prostate cancer — Medical News Today RSS/XML Feed
- Vitamin D compounds show promise for prevention of prostate cancer — EurekAlert! - Breaking News
- New treatment options for patients with prostate cancer — EurekAlert! - Biology
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol